| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Small Animal Medicine and Surgery (AK) and Veterinary Pathobiology (BRW), College of Veterinary Medicine, Texas A&M University, College Station, TX; IHC Services, Smithville, TX (JW); and Center for Cancer Causation and Prevention, AMC Cancer Research Center, and University of Colorado Cancer Center, Denver, CO (JFM)
We evaluated the expression of vimentin, S100a, and Melan A/MART-1 (melanoma antigen recognized by T cells 1) in seven cell lines established independently from dogs with canine melanoma. We also compared routine immunostaining of 29 clinical specimens from melanoma cases using vimentin, S100a, and neuron-specific enolase (NSE) with staining for Melan A/MART-1 as part of a diagnostic panel. All the cell lines were positive for expression of vimentin and S-100a. MelanA/MART-1 expression was seen consistently in only two of the seven cell lines. Staining for Melan A/MART-1 was most intense near areas of heavy melanin pigmentation. All except one of the clinical specimens were positive for vimentin. S100a was expressed in the majority of both pigmented (15/20, 75%) and amelanotic (8/9, 88.8%) tumors. Seventeen of 29 (58.6%) tumors were positive for NSE. Melan A/MART-1 was expressed in 18/29 (62%) tumors, including 90% of pigmented tumors, but in no amelanotic tumors. Intensity of Melan A/MART-1 staining correlated positively with biologic behavior, with seven malignant tumors showing negative to weak staining and 10 benign tumors showing moderate to strong staining. Three malignant tumors showed moderate to intense staining for Melan A/MART-1. Our results suggest that expression of Melan A/MART-1 may be unstable in cultured cell lines. Assessment of both S100a and Melan A/MART-1 expression is useful to confirm a diagnosis of canine melanoma, and Melan A/MART-1 may be especially informative regarding the biologic behavior of these tumors.
Key words: Dogs; immunohistochemistry; lineage markers; melanoma.
Reprint requests from Dr. J. F. Modiano, Center for Cancer Causation and Prevention, AMC Cancer Research Center, 1600 Pierce Street, Denver, CO 80214 (USA).
This article has been cited by other articles:
 |
|
 |
|
  J. R. Latendresse, L. Muskhelishvili, A. Warbritton, and W. H. Tolleson Two Cases of Uveal Amelanotic Melanoma in Transgenic Tyr-HRAS+ Ink4a/Arf Heterozygous Mice Toxicol Pathol, October 1, 2007; 35(6): 825 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Avallone, P. Helmbold, M. Caniatti, D. Stefanello, R. C. Nayak, and P. Roccabianca The Spectrum of Canine Cutaneous Perivascular Wall Tumors: Morphologic, Phenotypic and Clinical Characterization Vet. Pathol., September 1, 2007; 44(5): 607 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sanchez, G. A. Ramirez, A. J. Buendia, M. Vilafranca, C. M. Martinez, J. Altimira, and J. A. Navarro Immunohistochemical Characterization and Evaluation of Prognostic Factors in Canine Oral Melanomas with Osteocartilaginous Differentiation Vet. Pathol., September 1, 2007; 44(5): 676 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Choi and D. F. Kusewitt Comparison of Tyrosinase-related Protein-2, S-100, and Melan A Immunoreactivity in Canine Amelanotic Melanomas Vet. Pathol., November 1, 2003; 40(6): 713 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Mikaelian and V. Wong Follicular Stem Cell Carcinoma: Histologic, Immunohistochemical, Ultrastructural, and Clinical Characterization in 30 Dogs Vet. Pathol., July 1, 2003; 40(4): 433 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Smith, M. H. Goldschmidt, and P. M. McManus A Comparative Review of Melanocytic Neoplasms Vet. Pathol., November 1, 2002; 39(6): 651 - 678. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
